Introduction to Anti-VEGF Therapy in Uveitis

Managing the multifaceted nature of intraocular inflammation requires more than just traditional immunosuppression. Anti-VEGF therapy in uveitis has emerged as a crucial adjunctive tool. Specifically, it targets the vascular complications that often lead to irreversible vision loss. By neutralizing vascular endothelial growth factor (VEGF), these agents rapidly reduce vascular permeability. Moreover, they suppress pathological neovascularization. Because of this, clinicians can achieve faster visual stabilization in acute scenarios.

Role in Managing Complications with Anti-VEGF Therapy in Uveitis

Clinicians frequently encounter uveitic macular edema (UME) and inflammatory choroidal neovascularization (iCNV). While corticosteroids remain the primary defense, anti-VEGF therapy in uveitis offers a valuable alternative for steroid-intolerant patients. Furthermore, these agents address retinal neovascularization (RNV) associated with ischemic vasculitis. Consequently, patients experience anatomical stabilization. In addition, these gains might otherwise be elusive with steroids alone. Therefore, integrating these agents into standard care improves long-term outcomes.

Safety and Future Considerations

Despite the clinical benefits, safety monitoring remains paramount. Potential risks include sterile intraocular inflammation and, rarely, endophthalmitis. However, evolving delivery methods, such as sustained-release formulations, promise to mitigate these risks. Additionally, research continues to refine the integration of these biologics with systemic therapies. Specifically, combining them with antimicrobial or immunosuppressive drugs ensures better control. Consequently, both the underlying inflammation and the secondary vascular pathology receive effective treatment.

Frequently Asked Questions

1. Which uveitic complications benefit most from anti-VEGF agents?

Anti-VEGF agents are particularly effective for uveitic macular edema (UME), inflammatory choroidal neovascularization (iCNV), and retinal neovascularization (RNV) secondary to ischemia.

2. Can anti-VEGF therapy replace corticosteroids in uveitis?

No, they are typically used as adjuncts. While they treat vascular complications, corticosteroids or immunosuppressants are usually necessary to control the underlying inflammatory process.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Kawali A et al. Anti-vascular endothelial growth factor therapy in uveitis: Bridging inflammation and vascular pathology. Indian J Ophthalmol. 2026 May 01. doi: 10.4103/IJO.IJO_2975_25. PMID: 42054087.

2. Sahay P, et al. Inflammatory choroidal neovascularization in Indian eyes: Etiology, clinical features, and outcomes to anti-vascular endothelial growth factor. Indian J Ophthalmol. 2018;66(12):1800-1806.

3. Mesquida M, et al. Treatment Outcomes of Anti-VEGF Agents for Non-Infectious Uveitic Macula Edema. Invest Ophthalmol Vis Sci. 2022;63(7):3210-A0436.